2Dapoigny M, Ahitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozlne versus placebo in treatment of irritable bowel syndrome. A multiceuter dose-response study[J]. Dig Dis Sci, 1995,40(10) : 2244 - 2249.
3Wingate D, Hongo M, Kellow J, et al. Working party report. Disorders of gastrointestinal motility:Towards a new classification [ J ]. J of Gastroenterology and Hepatology, 2002,17 ( Suppl ): 1 - 14.
4Dmssman, DA, Corasziari E, Talley N J, et al . Rome II : The functional gastrointestinal disorders[M]. 2nd ed. McLean, Virginia: Degnon and Associates. 2000.
5Tsubouchi T, Saito T, Mizutani F, et al. Stimulatory Action of Itopride Hydrochlofide on Colonic Motor Activity In Vitro and In Vivo[J]. J Pharmacol Exp Ther,2003, Apt 30 ; [epub ahead of print].
6Dr. David S. Greenbaum MD,James E. Mayle MD,Lawrence E. Vanegeren PhD,John A. Jerome PhD,Joan W. Mayor RN,Ruth B. Greenbaum MN,Robert W. Matson MS,Gary E. Stein PharmD,Howard A. Dean DO,Nancy A. Halvorsen MD,Lionel W. Rosen MD. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo[J] 1987,Digestive Diseases and Sciences(3):257～266
7Dr. Lucien R. Jacobs MB,MSc,MRCP. Differential effects of dietary fibers on rat intestinal circular muscle cell size[J] 1985,Digestive Diseases and Sciences(3):247～252
8J. Patrick Herrington MD,Dr. Theodore W. Burns MD,Luis A. Balart MD. Chest pain and dysphagia in patients with prolonged peristaltic contractile duration of the esophagus[J] 1984,Digestive Diseases and Sciences(2):134～140
